ZeNix: Pretomanid, Bedaquiline, and Varied Doses and Durations of Linezolid in Highly Resistant TB

July 18-21, 2021; Virtual
Reduced doses and/or shorter durations of linezolid are associated with similar efficacy but improved safety.
Format: Microsoft PowerPoint (.ppt)
File Size: 231 KB
Released: July 26, 2021

Acknowledgements

Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Produced in collaboration with
Supported by educational grants from
Gilead Sciences, Inc.
Janssen Therapeutics, Division of Janssen Products, LP
Merck Sharp & Dohme Corp.
ViiV Healthcare

Related Content

Brief review of clinical trial results of MVA-BN-RSV vaccine for RSV in older adults, from Clinical Care Options (CCO)

Ting Shi, PhD Released: August 18, 2022

Download slides reviewing the latest data and guidance on COVID-19 diagnosis and transmission, from Clinical Care Options (CCO)

Arthur Kim, MD Sharon R. Lewin, AO, FRACP, PhD, FAHMS Kristen Marks, MD Renslow Sherer, MD Released: August 16, 2022

Download slides reviewing the latest data and guidance on COVID-19 symptoms and clinical manifestations, from Clinical Care Options (CCO)

Arthur Kim, MD Sharon R. Lewin, AO, FRACP, PhD, FAHMS Kristen Marks, MD Renslow Sherer, MD Released: August 9, 2022

Download slides reviewing the latest data and guidance on COVID-19 prevention and treatment in special populations, from Clinical Care Options (CCO)

Arthur Kim, MD Sharon R. Lewin, AO, FRACP, PhD, FAHMS Kristen Marks, MD Renslow Sherer, MD Released: August 8, 2022

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings